Skip to main content
Lotus Endometriosis Institute solid color logo
A beautiful landscape of lotus flowers

Postmenopausal Endometriosis: Risks and Key Insights

Understanding persistence after menopause and the rare risk of malignant change.

By Dr Steven Vasilev
A silver‑haired woman reviews a postmenopausal care folder at a sunlit home desk with a calendar, pathology report, and a “follow‑up” note, conveying calm vigilance about the rare risk of malignant change.

Postmenopausal Malignant Transformation of Endometriosis


Endometriosis is a condition that causes pain and infertility and predominantly affects premenopausal women. Estimates suggest that up to 10% of women worldwide experience the condition during their reproductive years. Although postmenopausal endometriosis is much less common, studies indicate it may still occur in approximately 2.5% of women, dispelling the misconception that endometriosis is exclusively a disease of younger women.


Despite being a benign disorder, endometriosis carries a risk of malignant transformation at all ages. This discussion explores the potential for such transformation in the postmenopausal population.


Understanding Endometriosis and Menopause


Postmenopausal endometriosis refers to the occurrence or persistence of endometriosis symptoms after menopause, which typically occurs around age 50 and is defined by the cessation of menstrual cycles for twelve consecutive months. After menopause, ovarian estrogen production becomes minimal, and estrogen is generally considered essential for the growth of endometriotic tissue. As a result, many cases naturally diminish. However, for some postmenopausal women, endometriosis persists or even appears de novo.


The causes of endometriosis in younger women remain controversial and incompletely defined. Through uncertain but likely multifactorial mechanisms, endometriosis is characterized by ectopic endometrial-like tissue growing outside the uterus. While one might expect the hypoestrogenic state associated with menopause to lessen symptoms, this is not universally observed.


In postmenopausal women, several mechanisms may contribute to endometriosis. Residual disease that began before menopause can continue due to persistence of lesions that respond to factors other than estrogen or because of heightened sensitivity to even low estrogen levels. Exogenous estrogen from hormone replacement therapy (HRT) may stimulate endometrial cells; estrogen-only regimens, in particular, can reactivate implants or potentially initiate new growths. Endogenous estrogen production also plays a role because adipose tissue can convert other hormones into estrogen. Women with higher amounts of adipose tissue might generate enough estrogen to promote endometriosis, and fat can store xeno-estrogens from certain toxins and release them over time. Moreover, the tissue microenvironment around endometriotic lesions can support local estrogen production.


Worried About Postmenopausal Endometriosis?

Our specialists are here to help you understand your condition and explore your treatment options.

Schedule Your Consult

Malignant Transformation: A Rare but Possible Event


Endometriosis is overwhelmingly benign, yet research has shown an increased risk of certain ovarian cancers among women with endometriosis, especially clear cell and endometrioid ovarian carcinomas.


Multiple factors may influence the likelihood of malignant transformation. The duration of endometriosis matters because prolonged presence of lesions increases cumulative time in an inflammatory state, and chronic inflammation is a known contributor to cancer development. As age advances, overall cancer risk rises, so persistent endometriosis after menopause hypothetically compounds this risk. Exogenous estrogen exposure through HRT can stimulate lesion growth and may contribute to malignant change, although this has not been definitively proven and is complicated by individual differences in estrogen levels and receptor activity.


Genetic and epigenetic influences are also important. Certain mutations may predispose some women to both deeply invasive endometriosis and ovarian cancer, creating an area of overlap between the two conditions. Epigenetic regulation, which governs gene activation and is shaped by environmental exposures, likely contributes over time, with a potential cumulative effect of active mutations across the years. Among the notable genetic factors, PTEN functions as a tumor suppressor and is found mutated in both endometriosis and in endometrioid and clear cell ovarian cancers; loss of PTEN function can drive uncontrolled cell growth and may facilitate malignant transformation. ARID1A mutations, commonly identified in endometriosis-associated ovarian cancers, disrupt chromatin remodeling and DNA repair, thereby promoting oncogenesis. KRAS and BRAF mutations, implicated in the pathogenesis of multiple cancers, have been detected in benign endometriotic lesions and may participate in early steps toward malignancy. Inherited mutations in BRCA1 and BRCA2, well known for their association with breast and ovarian cancers, may also increase the risk of developing endometriosis and its potential progression to malignancy.


Conclusions


Although less common than in premenopausal women, postmenopausal endometriosis remains clinically meaningful. The absolute risk of malignant transformation is very low, yet it underscores the value of regular monitoring and consultations with endometriosis specialists for postmenopausal women who have endometriosis or symptoms suggestive of it. When postmenopausal endometriosis is suspected or diagnosed—particularly if it appears invasive or is accompanied by unusual symptoms or pelvic masses—seeking evaluation from a gynecologic oncologist is a prudent step.

References

  1. Bulun SE. Endometriosis. N Engl J Med. 2009;360(3):268–279. DOI: 10.1007/s00210-025-04935-w

  2. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13(4):385–394. DOI: 10.1016/S1470-2045(11)70404-1

  3. Giannella L, Marconi C, Di Giuseppe J, et al. Malignant Transformation of Postmenopausal Endometriosis: A Systematic Review of the Literature. Cancers (Basel). 2021 Aug 10;13(16):4026. DOI: 10.3390/cancers13164026

  4. Giannella L, Marconi C, Di Giuseppe J, et al. The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data. Gynecol Oncol. 2011;123(1):157–163. DOI: 10.1016/j.ygyno.2011.06.017

  5. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000;60(24):7052–7056. PMID: 11156411

  6. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532–1543. DOI: 10.3390/biom13081253

  7. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med. 2005;11(1):63–70. DOI: 10.1038/nm1173

  8. Saha R, Pettersson H, Svedberg P, et al. Endometriosis and the risk of ovarian and endometrial adenocarcinomas: a meta-analysis. BMJ Open. 2020;10(4):e034760.

Quick Answers

Does adenomyosis get worse during perimenopause?

Adenomyosis can feel worse during perimenopause for some patients—not because it always “progresses” rapidly, but because hormone fluctuations and changing cycles can amplify the symptoms adenomyosis is known for, especially heavier or more erratic bleeding and worsening cramping or pelvic pressure. As periods become irregular, the pattern of pain may also change, which can be confusing when you’re used to clearly cyclical symptoms.


At the same time, perimenopause doesn’t guarantee worsening. Some people notice symptoms stabilize or improve as they transition fully into menopause, while others continue to have significant pain or bleeding—especially if adenomyosis overlaps with conditions like endometriosis or fibroids. If your symptoms are escalating, we can help clarify what’s driving them (often with targeted ultrasound and, when it matters, MRI) and talk through treatment paths that match your goals, including uterus-preserving options when appropriate and definitive options when they’re not.

Read full answer

How long should I wait to know if endometriosis treatment works?

It depends on what kind of “treatment” you mean—because treating endometriosis itself and managing endometriosis pain don’t always improve on the same timeline. Symptom-focused plans (like pain management strategies) can change how you feel relatively quickly, while disease-directed approaches may take longer to translate into steady, day-to-day relief. And even after technically successful treatment, pain can persist if the nervous system has become sensitized, so we look at the full picture rather than using one symptom as the only yardstick.


In general, we recommend judging progress using patterns over time—your flare frequency, intensity, function (sleep, work, activity), and how predictable your cycles and triggers feel—rather than one “good” or “bad” week. Tracking symptoms helps us see whether you’re trending in the right direction or whether we’re simply masking pain while the underlying drivers remain. If you’ve been cycling through treatments without durable improvement, our team can review your records and symptoms, clarify what the treatment is truly targeting, and map out what a reasonable trial period and next step should look like for your specific situation.

Read full answer

Can endometriosis surgery trigger early menopause?

Endometriosis excision surgery does not inherently cause early menopause, because menopause is driven by loss of ovarian function—not by removing endometriosis from the pelvis. That said, surgery can impact ovarian reserve in certain situations, especially when endometriosis involves the ovaries (endometriomas) and the procedure requires removing cyst walls or scarred tissue that’s intertwined with healthy ovary.


The biggest menopause-related risk is when an ovary must be removed (oophorectomy) or when ovarian blood supply or tissue is significantly compromised during complex ovarian surgery. Our approach prioritizes meticulous ovarian-sparing excision whenever it’s safe and appropriate, using techniques designed to preserve as much healthy ovarian tissue as possible—while still removing disease at its root.


If you’re worried about early menopause, the most important step is clarifying whether your disease appears ovarian, how many ovaries are involved, and what the realistic surgical plan is (cyst excision vs ovarian preservation vs removal). You can explore more about how we tailor surgery to protect fertility and long-term hormonal health, or reach out to schedule a consultation so we can review your imaging, goals, and risks in detail.

Read full answer

Can endometriosis develop later in life?

Yes—endometriosis can develop or become noticeable later in life. While many people first have symptoms in the teen years or 20s–30s, endometriosis can show up in peri-menopause, and it can also persist or even appear after menopause (less commonly). The idea that it always “burns out” once periods stop isn’t reliable.


Later-in-life endometriosis may look different than the classic cycle-linked pain. Some people notice more constant pelvic pain, bloating or bowel changes, urinary urgency or bladder discomfort, pain with sex, or even bleeding after menopause. Hormone therapy can sometimes reactivate previously quiet disease, and endometriosis tissue can also produce estrogen locally, which may help it stay active even when ovarian estrogen is low.


If you’re developing new pelvic, bowel, or bladder symptoms as you age—or you’ve had symptoms for years that were never fully explained—our team can help you sort through the possibilities and evaluate for endometriosis and related conditions. If endometriosis is part of the picture, we’ll walk you through what that means and which treatment paths (including minimally invasive excision surgery when appropriate) fit your goals and stage of life.

Read full answer

Does endometriosis go away after menopause?

Not always. While menopause lowers ovarian estrogen and many people do notice improvement, endometriosis can persist—and in some cases symptoms can even begin around peri‑menopause or after periods stop. That’s because endometriosis isn’t only driven by the ovaries; lesions can be highly sensitive to low estrogen levels, and some tissue can produce estrogen locally in the area of disease.


After menopause, symptoms also tend to look less “cyclical” and more like ongoing pelvic pain, bowel or bladder irritation, bloating, painful sex, or occasional bleeding. Hormone therapy can sometimes reactivate symptoms in susceptible patients, and long‑standing disease may leave behind fibrosis/scar tissue that won’t respond to medications. If you’re still having symptoms in peri‑ or post‑menopause, our team can help clarify whether you’re dealing with active endometriosis, adhesions/fibrosis, or another overlapping condition—and discuss whether excision surgery, supportive care, or a tailored plan around hormones makes the most sense.

Read full answer

Reach Out

Have a question?

Dr. Steven Vasilev delivers best-in-class endometriosis guidance and a personalized treatment plan—built on evidence and your unique biology.


Led by Steven Vasilev, MD—an internationally recognized endometriosis specialist & MIGS surgeon—Lotus Endometriosis Institute is virtual-forward, with many patients traveling nationally for care. Clinical evaluation and surgical treatment are provided in California.

Santa Monica, CA

2121 Santa Monica Blvd, Santa Monica, CA 90404

Operating Hours

8:00 am - 5:00 pm
Monday - Friday

Arroyo Grande, CA

154 Traffic Way, Arroyo Grande, CA 93420